Anika Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Anika develops, manufactures, and commercializes hyaluronic-acid-based products for tissue protection, healing, and repair, including orthobiologics, dermal, ophthalmic, surgical, and veterinary products. This unaudited Form 10-Q covers the three and nine months ended September 30, 2012, compared with the corresponding 2011 periods.
Key Financial Metrics
| Metric | Q3 2012 | Q3 2011 | 9M 2012 | 9M 2011 |
|---|---|---|---|---|
| Total revenue | $14.8 million | $18.5 million | $48.8 million | $46.3 million |
| Product revenue | $14.1 million | $17.8 million | $46.6 million | $44.2 million |
| Operating income | $2.7 million | $4.8 million | $11.9 million | $9.1 million |
| Net income | $1.6 million | $3.0 million | $7.3 million | $5.6 million |
| Diluted EPS | $0.11 | $0.22 | $0.51 | $0.41 |
| Operating margin | 18.5% | 26.1% | 24.5% | 19.5% |
| Net margin | 11.1% | 16.1% | 15.0% | 12.0% |
- Product gross margin was 49% in the third quarter and 53% for the first nine months, compared with 58% and 56%, respectively, in the prior-year periods.
- Research and development expense was $1.2 million in the quarter and $4.0 million year-to-date; SG&A expense was $3.6 million and $11.1 million, respectively.
- Cash provided by operating activities was $5.7 million for the first nine months, compared with $2.9 million in 2011. Capital expenditures were $1.3 million.
- Cash and cash equivalents were $39.9 million at September 30, 2012, compared with $35.8 million at December 31, 2011. Working capital was approximately $56.2 million, versus $49.6 million at year-end 2011.
- Total debt was $10.0 million, consisting of $1.6 million current debt and $8.4 million long-term debt. The variable-rate credit agreement bears interest at LIBOR plus 1.25% or the lender’s prime rate and matures December 31, 2015, with a $5.2 million final installment.
Material Changes Versus the Prior Comparable Period
- Third-quarter revenue declined 20% primarily because a temporary Bedford manufacturing scale-up issue prevented the Company from filling all ORTHOVISC orders and because ophthalmic volumes declined under the revised Bausch & Lomb supply arrangement. Management estimated approximately $2.8 million of ORTHOVISC sales were deferred to the fourth quarter.
- Nine-month revenue increased 5%, led by higher orthobiologics, ophthalmic, and veterinary sales. Veterinary revenue increased 49% year-to-date, while dermal revenue declined 56%.
- Third-quarter operating income and net income declined 43% and 45%, respectively, reflecting lower revenue and gross margin. For the first nine months, operating income and net income increased 32% and 31%, respectively, due largely to higher revenue and lower R&D and SG&A spending.
- The manufacturing transition from the former Woburn facility to Bedford caused lost in-process ORTHOVISC inventory and reduced utilization. The Woburn facility closed in June 2012.
- Debt declined from $11.2 million at December 31, 2011, following $1.2 million of principal payments. Inventories increased to $8.9 million from $7.3 million.
- Effective tax rates increased to 38.6% for the quarter and 38.1% year-to-date, compared with 37.6% and 37.4%, respectively, primarily because of lower available tax credits and larger losses at Anika S.r.l.
Guidance, Outlook, Risks, and Unusual Items
- Management expected delayed ORTHOVISC orders to ship in the fourth quarter of 2012 and expected overall HYVISC revenue to exceed 2011 levels.
- Management expected full-year ophthalmic revenue to decline because Anika became a secondary supplier to Bausch & Lomb; Bausch & Lomb represented approximately 17% of nine-month 2012 product revenue.
- The Company planned to transfer additional Anika S.r.l. manufacturing to Bedford over the following two years, with anticipated gross-margin benefits beginning in the first half of 2013. It also expected 2012 capital spending to exceed 2011 levels.
- R&D spending was expected to increase as clinical trials and pipeline development expand. The Company expected to commence a CINGAL clinical trial in early 2013.
- MONOVISC U.S. approval remained uncertain. The FDA had requested additional information after a supervisory appeal meeting, and the Company was awaiting a decision on its PMA appeal.
- Genzyme litigation relating to MONOVISC was stayed in September 2012 pending resolution of related litigation. Management considered potential losses not probable and recorded no accrual. DePuy Mitek assumed certain litigation obligations under a 2011 agreement.
- The Merogel Injectable dispute with Medtronic was settled in August 2012. The Company is pursuing indemnification from Fidia, which disputes liability; no accrual was recorded for the related contingencies.
- Key risks include FDA and foreign regulatory approvals, intellectual-property disputes, reliance on distributors and major customers, manufacturing transitions, foreign currency exposure, competition, reimbursement and healthcare cost controls, and the ability to manage Anika S.r.l.’s losses.
- Management stated that available cash, operating cash flow, and existing resources were adequate to support the business for the next twelve months. The filing reported no material changes to previously disclosed market risks or risk factors.
Important Facts for Investors to Verify
- Whether the deferred ORTHOVISC orders were shipped in the fourth quarter and whether Bedford manufacturing achieved expected capacity and margin improvements.
- The continuing effect of reduced Bausch & Lomb volumes and the concentration of product revenue among major customers and distributors.
- The status and potential commercial impact of the MONOVISC FDA appeal, related patent litigation, and any required clinical or regulatory spending.
- Progress, costs, and timing of transferring Anika S.r.l. production to Bedford and developing CINGAL and other pipeline products.
- Actual 2012 capital expenditures, debt repayments, covenant compliance, and sensitivity to variable interest rates.
- Resolution of Fidia’s indemnification and escrow-share dispute and any changes to the Company’s assessment of litigation contingencies.